Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
NCT ID: NCT02630121
Last Updated: 2025-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
52 participants
INTERVENTIONAL
2023-04-01
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion
NCT00584662
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
NCT01622569
Nasal Decongestion and Obstructive Sleep Apnea
NCT00630474
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
NCT01624662
Exploratory Subjective Sleep Study of a Prototype Nasal Dilator
NCT01122849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. The Flow Sensor, as part of the NOX T3 portable monitor, will be used to assess flow limitation of the upper airway through calculation of the flattening index, a marker of upper airway resistance.
2. The Congestion Quantifier 7 (CQ7) questionnaire will be used to assess for an improvement in nasal congestion based on symptoms from the prior week.
3. The Nasal Congestion Visual Analog Scale (VAS) will be used to identify the changes in the severity of nasal congestion on a day to day basis.
4. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) will be used to assess the impact of perennial rhinitis and nasal congestion on activities of daily living.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo/Fluticasone Propionate
Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
Placebo
Proportion of the subjects with 50% reduction in AHI.
Oxymetazoline Hydrochloride /Fluticasone Propionate
Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
Oxymetazoline Hydrochloride
Proportion of the subjects with 50% reduction in AHI.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxymetazoline Hydrochloride
Proportion of the subjects with 50% reduction in AHI.
Placebo
Proportion of the subjects with 50% reduction in AHI.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. At least a one year history of perennial allergic or non-allergic rhinitis.
3. Subjects must be on the maximum recommended doses of one of the following NGCS for at least one month. (See Table I)
4. AHI per hour of sleep \> 5 and \<15, minimum SpO2 88, indicating mild obstructive sleep apnea).
5. Average Nasal Congestion VAS of \> 3-10 indicating moderate to severe nasal congestion between visits 1 and 2 based on daily symptoms (average of 7 scores).
6. Average Congestion Quantifier 7 score of 7 between visits 1 and 2 based on weekly symptoms (average of 2 scores).
7. Willingness to participate as indicated by signed informed consent.
Exclusion Criteria
2. Subjects receiving allergen immunotherapy but not on a stable maintenance regimen for at least 30 days before the first study visit.
3. If the subject has perennial allergic rhinitis, he/she should not be entered into this study eight weeks before, during, or six weeks after any seasonal exacerbation.
4. Women who are pregnant or lactating.
5. Other known nasal diseases likely to affect deposition of oxymetazoline such as sinusitis, nasal polyps, or major nasal structural malformations.
6. Respiratory tract infections in the last 14 days.
7. Infections requiring antibiotics in the last 14 days.
8. Asthma or chronic obstructive pulmonary disease (COPD) requiring roflumilast or more than the recommended doses of inhaled corticosteroids, beta agonists, or antimuscarinic agents.
9. No systemic glucocorticosteroids for one month prior or during the study.
10. Cardiovascular disease with uncontrolled hypertension (BP160/80), arrhythmias and/or congestive heart failure.
11. Insulin-dependent diabetes mellitus and/or diabetic retinopathy.
12. Subjects with mild OSA (AHI 5-14) and SpO2 \<88 for \> 5 min during sleep that is identified during the screening portable sleep study.
13. Hypertension requiring more than two drugs, with the exception of hydrochlorothiazide, to achieve control.
14. A history of drug or alcohol abuse within the past 5 years.
15. Subjects who are currently abusing alcohol, illicit drugs, benzodiazepines, or narcotics.
16. Inability to cooperate, comply with study procedures or communicate with the investigator to successfully complete the study.
17. A history of benign prostate hypertrophy necessitating treatment.
18. A history of psychiatric problems which, in the opinion of the investigators, would impair participation in the study.
19. Subjects with a planned hospitalization during the study.
20. An infirmity, disability, or geographical location which seems likely to prevent regular attendance for subject visits.
21. Subjects with obstructive sleep apnea syndrome requiring CPAP therapy.
22. Subjects diagnosed with central sleep apnea (\> 5 central events per hour) or moderate to severe OSA (AHI \> 15) and SpO2 \<88 for \> 5 min during sleep identified during screening.
23. Use of the following medications within the time period specified below prior to Day -7 (Table 2).
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of South Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Usf Asthma Allergy and Immunology Cru
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00001844
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.